蛋白酶体抑制剂在肺癌治疗中的研究进展(1)
[摘要] 泛素-蛋白酶体通路(UPP)是细胞内重要的蛋白质降解系统。研究表明UPP参与恶性肿瘤多种细胞生物学过程的调节，影响其发生、发展。蛋白酶体抑制剂通过阻断UPP，可抑制肿瘤细胞生长，成为肿瘤治疗的新方法。肺癌在人类癌症死亡原因中居于首位，蛋白酶体抑制剂对肺癌的疗效研究仍在进行，其作用机制复杂，与NF-κB的下调、细胞周期调控、PTEN/PI3K/Akt通路和P53的调节等有关。本文对蛋白酶体抑制剂在肺癌治疗的新进展进行综述。
[关键词] 蛋白酶体抑制剂；泛素-蛋白酶体通路；肺癌；作用机制
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2016)08(b)-0038-04
[Abstract] The ubiquitin-proteasome pathway is the principle pathway for intracellular protein degradation. Research shows that ubiquitin-proteasome pathway plays a significant role in the genesis and progression of malignancy by regulating many processes of cellular biology. Proteasome inhibitors targeting the ubiquitin-proteasome pathway can inhibit tumorous cellular growth ......
您现在查看是摘要页，全文长 4078 字符。
[关键词] 蛋白酶体抑制剂；泛素-蛋白酶体通路；肺癌；作用机制
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2016)08(b)-0038-04
[Abstract] The ubiquitin-proteasome pathway is the principle pathway for intracellular protein degradation. Research shows that ubiquitin-proteasome pathway plays a significant role in the genesis and progression of malignancy by regulating many processes of cellular biology. Proteasome inhibitors targeting the ubiquitin-proteasome pathway can inhibit tumorous cellular growth ......
您现在查看是摘要页，全文长 4078 字符。